"Cardiovascular Diseases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Descriptor ID |
D002318
|
| MeSH Number(s) |
C14
|
| Concept/Terms |
Cardiovascular Diseases- Cardiovascular Diseases
- Cardiovascular Disease
- Disease, Cardiovascular
- Diseases, Cardiovascular
|
Below are MeSH descriptors whose meaning is more general than "Cardiovascular Diseases".
Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Diseases".
This graph shows the total number of publications written about "Cardiovascular Diseases" by people in this website by year, and whether "Cardiovascular Diseases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 2 | 3 |
| 1999 | 0 | 4 | 4 |
| 2000 | 4 | 2 | 6 |
| 2001 | 3 | 3 | 6 |
| 2002 | 8 | 2 | 10 |
| 2003 | 8 | 6 | 14 |
| 2004 | 8 | 4 | 12 |
| 2005 | 13 | 6 | 19 |
| 2006 | 6 | 9 | 15 |
| 2007 | 11 | 8 | 19 |
| 2008 | 17 | 7 | 24 |
| 2009 | 17 | 4 | 21 |
| 2010 | 14 | 9 | 23 |
| 2011 | 18 | 10 | 28 |
| 2012 | 18 | 8 | 26 |
| 2013 | 20 | 8 | 28 |
| 2014 | 25 | 5 | 30 |
| 2015 | 21 | 5 | 26 |
| 2016 | 19 | 6 | 25 |
| 2017 | 20 | 5 | 25 |
| 2018 | 25 | 5 | 30 |
| 2019 | 28 | 5 | 33 |
| 2020 | 30 | 5 | 35 |
| 2021 | 31 | 8 | 39 |
| 2022 | 26 | 0 | 26 |
| 2023 | 33 | 2 | 35 |
| 2024 | 17 | 7 | 24 |
| 2025 | 7 | 1 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiovascular Diseases" by people in Profiles.
-
Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 Jun 01; 64(6):3434-3443.
-
Community intervention to reduce cardiovascular disease in Chicago (CIRCL-Chicago): protocol for a type 3 hybrid effectiveness-implementation study using a parallel cluster-randomized trial design. Implement Sci. 2025 05 05; 20(1):19.
-
Advancing Chrononutrition for Cardiometabolic Health: A 2023 National Heart, Lung, and Blood Institute Workshop Report. J Am Heart Assoc. 2025 May 06; 14(9):e039373.
-
The Effectiveness of a Race-Based Stress Reduction Intervention on Improving Stress-Related Symptoms and Inflammation in African American Women at Risk for Cardiometabolic Disease: Protocol for Recruitment and Intervention for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Apr 18; 14:e65649.
-
Circulating follistatin-like 3 and its association with postpartum cardiovascular dysfunction and severe maternal morbidity. Pregnancy Hypertens. 2025 Jun; 40:101206.
-
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum. 2025 Mar 07; 6(3):e245586.
-
Cardiometabolic disease risk in gorillas is associated with altered gut microbial metabolism. NPJ Biofilms Microbiomes. 2025 Feb 21; 11(1):33.
-
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis. BMJ Open Gastroenterol. 2025 Jan 08; 12(1).
-
Accelerated development of cardiovascular risk factors mediates risk for major adverse cardiovascular events in posttraumatic stress disorder. Brain Behav Immun. 2025 Mar; 125:148-157.
-
TSH Trajectories During Levothyroxine Treatment in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) Cohort. J Clin Endocrinol Metab. 2024 Nov 18; 109(12):3065-3075.